Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 23858-23871

  Barna, Barbara P ^a   Huizar, Isham ^a,b   Malur, Anagha ^a   McPeek, Matthew ^a   Marshall, Irene ^a   Jacob, Mark ^a   Dobbs, Larry ^a   Kavuru, Mani S ^a,c   Thomassen, Mary Jane ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Alveolar macrophages; Carbon nanotubes; Sarcoidosis; Twist1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MULTI WALLED NANOTUBE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR TWIST; CARBON NANOTUBE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ANIMAL CELL; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG ALVEOLUS MACROPHAGE; LUNG SARCOIDOSIS; MALE; MOUSE; POLYMERASE CHAIN REACTION; PROTEIN MICROARRAY; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; LUNG LAVAGE; MACROPHAGE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; TOXICITY; UPREGULATION;

ADULT; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NANOTUBES, CARBON; PPAR GAMMA; RNA, MESSENGER; SARCOIDOSIS, PULMONARY; TWIST TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84889859083     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141223858     Document Type: Article

References (46)

1. De Volder, M.F.; Tawfick, S.H.; Baughman, R.H.; Hart, A.J. Carbon nanotubes: Present and future commercial applications. Science 2013, 339, 535-539.
2. Lam, C.W.; James, J.T.; McCluskey, R.; Arepalli, S.; Hunter, R.L. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit. Rev. Toxicol. 2006, 36, 189-217.
3. Bonner, J.C. Carbon nanotubes as delivery systems for respiratory disease: Do the dangers outweigh the potential benefits? Expert Rev. Respir. Med. 2011, 5, 779-787.
4. Shvedova, A.A.; Kisin, E.R.; Mercer, R.; Murray, A.R.; Johnson, V.J.; Potapovich, A.I.; Tyurina, Y.Y.; Gorelik, O.; Arepalli, S.; Schwegler-Berry, D.; et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 289, L698-L708.
5. Mercer, R.R.; Hubbs, A.F.; Scabilloni, J.F.; Wang, L.; Battelli, L.A.; Friend, S.; Castranova, V.; Porter, D.W. Pulmonary fibrotic response to aspiration of multi-walled carbon nanotubes. Part. Fibre Toxicol. 2011, doi:10.1186/1743-8977-8-21.
6. Wang, X.; Katwa, P.; Podila, R.; Chen, P.; Ke, P.C.; Rao, A.M.; Walters, D.M.; Wingard, C.J.; Brown, J.M. Multi-walled carbon nanotube instillation impairs pulmonary function in C57BL/6 mice. Part. Fibre Toxicol. 2011, doi:10.1186/1743-8977-8-24.
7. Huizar, I.; Malur, A.; Midgette, Y.A.; Kukoly, C.; Chen, P.; Ke, P.C.; Podila, R.; Rao, A.M.; Wingard, C.J.; Dobbs, L.; et al. Novel murine model of chronic granulomatous lung inflammation elicited by carbon nanotubes. Am. J. Respir. Cell Mol. Biol. 2011, 45, 858-866.
8. Chen, E.S.; Moller, D.R. Sarcoidosis-Scientific progress and clinical challenges. Nat. Rev. Rheumatol. 2011, 7, 457-467.
9. Bresnitz, E.A.; Stolley, P.D.; Israel, H.L.; Soper, K. Possible risk factors for sarcoidosis: A case-control study. Ann. N. Y. Acad. Sci. 1986, 465, 632-642.
10. Prezant, D.J.; Dhala, A.; Goldstein, A.; Janus, D.; Ortiz, F.; Aldrich, T.K.; Kelly, K.J. The incidence, prevalence, and severity of sarcoidosis in New York city firefighters. Chest 1999, 116, 1183-1193.
11. Izbicki, G.; Chavko, R.; Banauch, G.I.; Weiden, M.D.; Berger, K.I.; Aldrich, T.K.; Hall, C.; Kelly, K.J.; Prezant, D.J. World trade center "sarcoid-like" granulomatous pulmonary disease in New York city fire department rescue workers. Chest 2007, 131, 1414-1423.
12. Wu, M.; Gordon, R.E.; Herbert, R.; Padilla, M.; Moline, J.; Mendelson, D.; Litle, V.; Travis, W.D.; Gil, J. Case report: Lung disease in World Trade Center responders exposed to dust and smoke. Carbon nanotubes found in the lungs of World Trade Center patients and dust samples. Environ. Health Perspect. 2010, 118, 499-504.
13. Kunkel, S.; Lukacs, N.W.; Strieter, R.M.; Chensue, S.W. Animal models of granulomatous inflammation. Semin. Respir. Infect. 1998, 13, 221-228.
14. Shigehara, K.; Shijubo, N.; Ohmichi, M.; Takahashi, R.; Kon, S.; Okamura, H.; Kurimoto, M.; Hiraga, Y.; Tatsuno, T.; Abe, S.; et al. IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J. Immunol. 2001, 166, 642-649.
15. Zissel, G.; Prasse, A.; Muller-Quernheim, J. Sarcoidosis-Immunopathogenetic concepts. Semin. Respir. Crit. Care Med. 2007, 28, 3-14.
16. Fehrenbach, H.; Zissel, G.; Goldmann, T.; Tschernig, T.; Vollmer, E.; Pabst, R.; Muller-Quernheim, J. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur. Respir. J. 2003, 21, 421-428.
17. Culver, D.A.; Barna, B.P.; Raychaudhuri, B.; Bonfield, T.L.; Abraham, S.; Malur, A.; Farver, C.F.; Kavuru, M.S.; Thomassen, M.J. Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am. J. Respir. Cell. Mol. Biol. 2004, 30, 1-5.
18. Bonfield, T.L.; Farver, C.F.; Barna, B.P.; Malur, A.; Abraham, S.; Raychaudhuri, B.; Kavuru, M.S.; Thomassen, M.J. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am. J. Respir. Cell Mol. Biol. 2003, 29, 677-682.
19. Straus, D.S.; Glass, C.K. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28, 551-558.
20. Huizar, I.; Malur, A.; Patel, J.; McPeek, M.; Dobbs, L.; Wingard, C.; Barna, B.P.; Thomassen, M.J. The role of PPARγ in carbon nanotube-elicited granulomatous lung inflammation. Respir. Res. 2013, doi:10.1186/1465-9921-14-7.
21. Thisse, B.; El, M.M.; Perrin-Schmitt, F. The twist gene: Isolation of a Drosophila zygotic gene necessary for the establishment of dorsoventral pattern. Nucleic Acids Res. 1987, 15, 3439-3453.
22. Franco, H.L.; Casasnovas, J.; Rodriguez-Medina, J.R.; Cadilla, C.L. Redundant or separate entities?-Roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res. 2011, 39, 1177-1186.
23. Sosic, D.; Richardson, J.A.; Yu, K.; Ornitz, D.M.; Olson, E.N. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-γB activity. Cell 2003, 112, 169-180.
24. Crouser, E.D.; Culver, D.A.; Knox, K.S.; Julian, M.W.; Shao, G.; Abraham, S.; Liyanarachchi, S.; Macre, J.E.; Wewers, M.D.; Gavrilin, M.A.; et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 2009, 179, 929-938.
25. Palchevskiy, V.; Hashemi, N.; Weigt, S.S.; Xue, Y.Y.; Derhovanessian, A.; Keane, M.P.; Strieter, R.M.; Fishbein, M.C.; Deng, J.C.; Lynch, J.P., III; et al. Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis. Fibrogenesis Tissue Repair. 2011, doi:10.1186/1755-1536-4-10.
26. Petrek, M.; Kolek, V.; Szotkowska, J.; du Bois, R.M. CC and C chemokine expression in pulmonary sarcoidosis. Eur. Respir. J. 2002, 20, 1206-1212.
27. Barna, B.P.; Culver, D.A.; Abraham, S.; Malur, A.; Bonfield, T.L.; John, N.; Farver, C.F.; Drazba, J.A.; Raychaudhuri, B.; Kavuru, M.S.; et al. Depressed peroxisome proliferator-activated receptor gamma (PPARγ) is indicative of severe pulmonary sarcoidosis: Possible involvement of interferon gamma (IFN-γ). Sarcoidosis Vasc. Diffus. Lung Dis. 2006, 23, 93-100.
28. Rosenbaum, J.T.; Pasadhika, S.; Crouser, E.D.; Choi, D.; Harrington, C.A.; Lewis, J.A.; Austin, C.R.; Diebel, T.N.; Vance, E.E.; Braziel, R.M.; et al. Hypothesis: Sarcoidosis is a STAT1-mediated disease. Clin. Immunol. 2009, 132, 174-183.
29. Moller, D.R.; Forman, J.D.; Liu, M.C.; Noble, P.W.; Greenlee, B.M.; Vyas, P.; Holden, D.A.; Forrester, J.M.; Lazarus, A.; Wysocka, M.; et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J. Immunol. 1996, 156, 4952-4960.
30. Grohmann, U.; Belladonna, M.L.; Vacca, C.; Bianchi, R.; Fallarino, F.; Orabona, C.; Fioretti, M.C.; Puccetti, P. Positive regulatory role of IL-12 in macrophages and modulation by IFN-γ. J. Immunol. 2001, 167, 221-227.
31. Watford, W.T.; Hissong, B.D.; Bream, J.H.; Kanno, Y.; Muul, L.; O'Shea, J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 2004, 202, 139-156.
32. Persky, M.E.; Murphy, K.M.; Farrar, J.D. IL-12, but not IFN-α, promotes STAT4 activation and Th1 development in murine CD4+ T cells expressing a chimeric murine/human Stat2 gene. J. Immunol. 2005, 174, 294-301.
33. Nishioka, Y.; Manabe, K.; Kishi, J.; Wang, W.; Inayama, M.; Azuma, M.; Sone, S. CXCL9 and 11 in patients with pulmonary sarcoidosis: A role of alveolar macrophages. Clin. Exp. Immunol. 2007, 149, 317-326.
34. Liu, J.; Guan, X.; Ma, X. Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon γ-induced RANTES/CCl5 expression in macrophages. J. Biol. Chem. 2005, 280, 24347-24355.
35. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958-969.
36. Sica, A.; Mantovani, A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Investig. 2012, 122, 787-795.
37. Sharif, M.N.; Sosic, D.; Rothlin, C.V.; Kelly, E.; Lemke, G.; Olson, E.N.; Ivashkiv, L.B. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 2006, 203, 1891-1901.
38. Loza, M.J.; Brodmerkel, C.; du Bois, R.M.; Judson, M.A.; Costabel, U.; Drent, M.; Kavuru, M.; Flavin, S.; Lo, K.H.; Barnathan, E.S.; et al. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin. Vaccine Immunol. 2011, 18, 931-939.
39. Agostini, C.; Meneghin, A.; Semenzato, G. T-lymphocytes and cytokines in sarcoidosis. Curr. Opin. Pulm. Med. 2002, 8, 435-440.
40. Dai, H.; Guzman, J.; Chen, B.; Costabel, U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-α by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 2005, 127, 251-256.
41. Pozharskaya, V.; Torres-Gonzalez, E.; Rojas, M.; Gal, A.; Amin, M.; Dollard, S.; Roman, J.; Stecenko, A.A.; Mora, A.L. Twist: A regulator of epithelial-mesenchymal transition in lung fibrosis. PLoS One 2009, 4, e7559.
42. Bridges, R.S.; Kass, D.; Loh, K.; Glackin, C.; Borczuk, A.C.; Greenberg, S. Gene expression profiling of pulmonary fibrosis identifies Twist1 as an antiapoptotic molecular "rectifier" of growth factor signaling. Am. J. Pathol. 2009, 175, 2351-2361.
43. Bouhlel, M.A.; Derudas, B.; Rigamonti, E.; DiFvart, R.; Brozek, J.; Haulon, S.; Zawadzki, C.; Jude, B.; Torpier, G.; Marx, N.; et al. PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6, 137-143.
44. American Thoracic Society. Statement on sarcoidosis. Am. J. Respir. Crit. Care Med. 1999, 160, 736-755.
45. Thomassen, M.J.; Buhrow, L.T.; Connors, M.J.; Kaneko, F.T.; Erzurum, S.C.; Kavuru, M.S. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 1997, 17, 279-283.
46. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001, 25, 402-408.